1. |
Brink AJ. Epidemiology of carbapenem-resistant Gram-negative infections globally. Curr Opin Infect Dis, 2019, 32(6): 609-616.
|
2. |
Rojas A, Palacios-Baena ZR, López-Cortés LE, et al. Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis. Clin Microbiol Infect, 2019, 25(8): 964-970.
|
3. |
Ababneh MA, Rababa’h AM, Almomani BA, et al. A ten-year surveillance of P aeruginosa bloodstream infections in a tertiary care hospital: trends and risk factors for mortality. Int J Clin Pract, 2021, 75(9): e14409.
|
4. |
Suárez C, Peña C, Gavaldà L, et al. Influence of carbapenem resistance on mortality and the dynamics of mortality in Pseudomonas aeruginosa bloodstream infection. Int J Infect Dis, 2010, 14(Suppl 3): e73-78.
|
5. |
Horino T, Chiba A, Kawano S, et al. Clinical characteristics and risk factors for mortality in patients with bacteremia caused by Pseudomonas aeruginosa. Intern Med, 2012, 51(1): 59-64.
|
6. |
Callejas-Díaz A, Fernández-Pérez C, Ramos-Martínez A, et al. Impact of Pseudomonas aeruginosa bacteraemia in a tertiary hospital: mortality and prognostic factors. Med Clin (Barc), 2019, 152(3): 83-89.
|
7. |
Joo EJ, Kang CI, Ha YE, et al. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome. Microb Drug Resist, 2011, 17(2): 305-312.
|
8. |
Tuon FF, Gortz LW, Rocha JL. Risk factors for pan-resistant Pseudomonas aeruginosa bacteremia and the adequacy of antibiotic therapy. Braz J Infect Dis, 2012, 16(4): 351-356.
|
9. |
Diekema DJ, Hsueh PR, Mendes RE, et al. The microbiology of bloodstream infection: 20-year trends from the SENTRY antimicrobial surveillance program. Antimicrob Agents Chemother, 2019, 63(7): e00355-319.
|
10. |
Huttunen R, Åttman E, Aittoniemi J, et al. Nosocomial bloodstream infections in a Finnish tertiary care hospital: a retrospective cohort study of 2175 episodes during the years 1999-2001 and 2005-2010. Infect Dis (Lond), 2015, 47(1): 20-26.
|
11. |
Zavascki AP, Cruz RP, Goldani LZ. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect, 2005, 59(2): 96-101.
|
12. |
Lautenbach E, Synnestvedt M, Weiner MG, et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect Control Hosp Epidemiol, 2010, 31(1): 47-53.
|
13. |
施清怡. 碳青霉烯类不敏感铜绿假单胞菌血流感染危险因素及预后分析. 杭州: 浙江大学, 2019.
|
14. |
Zhang Y, Chen XL, Huang AW, et al. Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies. Emerg Microbes Infect, 2016, 5(3): e27.
|
15. |
Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis, 2019, 19(1): 56-66.
|
16. |
World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed. Geneva: World Health Organization, 2017.
|
17. |
Hu H, Zhang Y, Zhang P, et al. Bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing P. aeruginosa sequence type 463, associated with high mortality rates in China:a retrospective cohort study. Front Cell Infect Microbiol, 2021, 11: 756782.
|
18. |
Jeong SJ, Yoon SS, Bae IK, et al. Risk factors for mortality in patients with bloodstream infections caused by carbapenem-resistant Pseudomonas aeruginosa: clinical impact of bacterial virulence and strains on outcome. Diagn Microbiol Infect Dis, 2014, 80(2): 130-135.
|
19. |
Peña C, Suarez C, Gozalo M, et al. Prospective multicenter study of the impact of carbapenem resistance on mortality in Pseudomonas aeruginosa bloodstream infections. Antimicrob Agents Chemother, 2012, 56(3): 1265-1272.
|
20. |
Buehrle DJ, Shields RK, Clarke LG, et al. Carbapenem-resistant Pseudomonas aeruginosa bacteremia: risk factors for mortality and microbiologic treatment failure. Antimicrob Agents Chemother, 2016, 61(1): e01243-1216.
|
21. |
Suárez C, Peña C, Tubau F, et al. Clinical impact of imipenem-resistant Pseudomonas aeruginosa bloodstream infections. J Infect, 2009, 58(4): 285-290.
|
22. |
Aviv T, Lazarovitch T, Katz D, et al. The epidemiological impact and significance of carbapenem resistance in Pseudomonas aeruginosa bloodstream infections: a matched case-case-control analysis. Infect Control Hosp Epidemiol, 2018, 39(10): 1262-1265.
|
23. |
Garner JS, Jarvis WR, Emori TG, et al. CDC definitions for nosocomial infections, 1988. Am J Infect Control, 1988, 16(3): 128-140.
|
24. |
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis, 1987, 40(5): 373-383.
|
25. |
Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother, 2005, 49(2): 760-766.
|
26. |
Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for Gram-negative bacteraemia: a commentary. Int J Antimicrob Agents, 1999, 11(1): 7-12.
|
27. |
Doi Y. Treatment options for carbapenem-resistant Gram-negative bacterial infections. Clin Infect Dis, 2019, 69(Suppl 7): S565-S575.
|
28. |
Yang K, Xiao T, Shi Q, et al. Socioeconomic burden of bloodstream infections caused by carbapenem-resistant and carbapenem-susceptible Pseudomonas aeruginosa in China. J Glob Antimicrob Resist, 2021, 26: 101-107.
|
29. |
Morata L, Cobos-Trigueros N, Martínez JA, et al. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother, 2012, 56(9): 4833-4837.
|
30. |
Aliaga L, Mediavilla JD, Cobo F. A clinical index predicting mortality with Pseudomonas aeruginosa bacteraemia. J Med Microbiol, 2002, 51(7): 615-701.
|
31. |
苏冬梅, 赵雷, 董琳, 等. 铜绿假单胞菌血流感染 67 例临床及预后危险因素分析. 安徽医药, 2021, 25(1): 201-204.
|
32. |
王小雨, 任立军, 沈建飞, 等. 血流感染脓毒症患者炎症因子变化、病原菌分布特征及预后影响因素分析. 中国病原生物学杂志, 2020, 15(5): 587-591.
|
33. |
李瑛, 吕宇, 杨陵. 耐碳青霉烯类革兰阴性菌检出患者 30d 病死风险影响因素. 中华医院感染学杂志, 2020, 30(18): 2749-2753.
|
34. |
Tang PC, Lee CC, Li CW, et al. Time-to-positivity of blood culture: an independent prognostic factor of monomicrobial Pseudomonas aeruginosa bacteremia. J Microbiol Immunol Infect, 2017, 50(4): 486-493.
|
35. |
Lee CH, Su TY, Ye JJ, et al. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems. J Microbiol Immunol Infect, 2017, 50(5): 677-683.
|